Go Pro
NASDAQ:ACHV

Achieve Life Sciences (ACHV) Stock Price, News & Analysis

Achieve Life Sciences logo
$7.72 -0.11 (-1.34%)
As of 10:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Achieve Life Sciences Stock (NASDAQ:ACHV)

Advanced

Key Stats

Today's Range
$7.76
▼
$7.96
50-Day Range
$6.10
▼
$8.53
52-Week Range
$2.62
▼
$8.64
Volume
63,673 shs
Average Volume
1.35 million shs
Market Capitalization
$794.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cytisinicline, an investigational therapy designed to help adults stop smoking and address nicotine dependence. The company is listed on the Nasdaq Capital Market under the symbol ACHV.

Cytisinicline is a plant-derived small molecule that acts on neuronal nicotinic acetylcholine receptors involved in nicotine addiction. Achieve is evaluating the therapy in clinical studies for smoking cessation and potential support for quitting other forms of nicotine use. The company’s development programs have included the ORCA series of clinical trials conducted in the United States.

Achieve’s principal activities center on clinical development, regulatory preparation and potential commercialization of cytisinicline. Because the therapy remains an investigational product unless and until it receives applicable regulatory approvals, its availability and approved uses may change as development and regulatory review progress.

AI Generated. May Contain Errors.

Achieve Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

ACHV MarketRank™: 

Achieve Life Sciences scored higher than 65% of companies evaluated by MarketBeat, and ranked 297th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Achieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Achieve Life Sciences has a consensus price target of $15.00, representing about 92.2% upside from its current price of $7.80.

  • Amount of Analyst Coverage

    Achieve Life Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Achieve Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($0.91) to ($0.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Achieve Life Sciences is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Achieve Life Sciences is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Achieve Life Sciences has a P/B Ratio of 19.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Achieve Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    15.83% of the float of Achieve Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Achieve Life Sciences has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Achieve Life Sciences has recently decreased by 2.76%, indicating that investor sentiment is improving.
  • Dividend Yield

    Achieve Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Achieve Life Sciences does not have a long track record of dividend growth.

  • News Sentiment

    Achieve Life Sciences has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Achieve Life Sciences this week, compared to 4 articles on an average week.
  • Search Interest

    Only 8 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Achieve Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $175,115.00 in company stock.

  • Percentage Held by Insiders

    1.80% of the stock of Achieve Life Sciences is held by insiders.

  • Percentage Held by Institutions

    33.52% of the stock of Achieve Life Sciences is held by institutions.

  • Read more about Achieve Life Sciences' insider trading history.
Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACHV Stock News Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
Prévisions pour l’action Achieve Life Sciences
ACHV: Looking Ahead to Resubmission
See More Headlines

ACHV Stock Analysis - Frequently Asked Questions

Achieve Life Sciences' stock was trading at $4.97 at the beginning of 2026. Since then, ACHV shares have increased by 57.0% and is now trading at $7.8040.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted its quarterly earnings data on Tuesday, August, 11th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.64.

Achieve Life Sciences shares reverse split on the morning of Friday, July 31st 2020.The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional investors of Achieve Life Sciences include Frazier Life Sciences Management L.P. (7.40%), venBio Partners LLC (5.75%), BlackRock Inc. (5.14%) and Jupiter Topco LLC (2.67%). Insiders that own company stock include Thomas Braxton King, Richard Alistair Stewart, Mark K Oki, Cindy Jacobs, Jaime Xinos and Jerry Wan.
View institutional ownership trends
.

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Achieve Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Moderna (MRNA), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
8/11/2026
Today
9/25/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ACHV
CIK
949858
Employees
28
Year Founded
1995

Price Target and Rating

High Price Target
$19.00
Low Price Target
$12.00
Potential Upside/Downside
+91.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$54.65 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-511.12%
Return on Assets
-82.35%

Debt

Debt-to-Equity Ratio
0.87
Current Ratio
0.95
Quick Ratio
0.95

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.40 per share
Price / Book
19.58

Miscellaneous

Outstanding Shares
102,900,000
Free Float
101,050,000
Market Cap
$805.71 million
Optionable
Optionable
Beta
2.25

Social Links

10 Best Stocks to Own - Fall 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ACHV) was last updated on 9/25/2026 by MarketBeat.com Staff.
From Our Partners